Additionally, variations in TIM3, PD-1, and PD-L1 between baseline and post-NACT demonstrated a substantially positive relationship with one another, suggesting that dual targeting against PD-L1 and TIM3 may be a potentially beneficial choice for gastric cancer patients (98). The gene discussed is HAVCR2; the disease is gastric cancer.